Information Provided By:
Fly News Breaks for February 5, 2018
AXGN
Feb 5, 2018 | 09:03 EDT
William Blair analyst Kaila Krum initiated AxoGen with an Outperform rating saying the multiple is justified at current levels. AxoGen is a global leader in the peripheral nerve repair and regeneration industry, and sells a portfolio of solutions to treat patients with nerve injuries, Krum tells investors in a research note. The analyst believes the company should be able to grow 40%-plus in 2018 and "durably" in the mid-30% range over the next three-to-five years.
News For AXGN From the Last 2 Days
There are no results for your query AXGN